Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Polyrizon Ltd. ( (PLRZ) ) is now available.
On December 3, 2025, Polyrizon Ltd. announced positive preclinical results for its intranasal naloxone hydrogel, which demonstrated superior mucoadhesion compared to an existing marketed product. This advancement suggests potential for more reliable opioid overdose reversal in emergencies, reinforcing the company’s position in the biotechnology sector and highlighting the efficacy of its T&T hydrogel platform.
More about Polyrizon Ltd.
Polyrizon Ltd. is a biotechnology company specializing in the development of innovative intranasal products, particularly focusing on hydrogels that form a protective barrier in the nasal cavity. Their proprietary technologies, including Capture and Contain (C&C) and Trap and Target (T&T), are aimed at enhancing drug delivery and providing protection against viruses and allergens.
Average Trading Volume: 2,553,359
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.32M
See more insights into PLRZ stock on TipRanks’ Stock Analysis page.